Irv griffin, there are no.risks associated with your dual silencer drug and stabilizer drug therapy. I amin same regimen as are about 25% of those who are seen by competent experienced amyloidosis specialists.
July 7
Basically the same answer my Cardiologist gave me just two weeks ago (since I am taking both a stabilizer and a silencer). Thinking that it not be the "Standard of Care" for all, I have tried but have been unable to find info on the web about the benefits or risks from doing both at the same time. I am interested in contacting researchers to see if there is something I can do as as patient to help them answer the question about two therapies. The answer for me may not help me at all but I see a potential to help others in the future.
July 6
My insurannce company won't support two meds. Attruby is helping, but I also want Amvuttra. Any suggestions?
July 7
That's a really thoughtful question, and it's one that researchers and clinicians are actively thinking about too.
The short answer is that combining a TTR stabilizer like Vyndamax (tafamidis) with a gene silencer like Amvuttra (vutrisiran) hasn't yet been established as standard of care largely because the clinical Show Full Answer
That's a really thoughtful question, and it's one that researchers and clinicians are actively thinking about too.
The short answer is that combining a TTR stabilizer like Vyndamax (tafamidis) with a gene silencer like Amvuttra (vutrisiran) hasn't yet been established as standard of care largely because the clinical evidence to support it isn't there yet.
Here are some key reasons why: - Lack of clinical trial data — Combination therapy hasn't been rigorously tested in large-scale trials for wild-type ATTR amyloidosis specifically, so there's no strong evidence yet proving it's more effective than either drug alone.
- Amvuttra's approval is recent — Vutrisiran was only approved for ATTR cardiomyopathy (ATTR-CM) in March 2025, so combination studies are still in early stages.
- Each drug works differently — Vyndamax stabilizes the TTR protein to prevent misfolding, while Amvuttra reduces how much TTR the liver produces. Whether combining both approaches adds meaningful benefit is still being studied.
- Cost and access concerns — Both medications are expensive, and insurers may not cover combination therapy without strong clinical evidence backing it.
The medical community generally waits for solid trial data before making something "standard of care." It's absolutely worth raising this question with your care team, as treatment approaches are evolving quickly in this space.
July 6
Join
Your Privacy Choices
